News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TRACON Pharmaceuticals, Inc. Appoints William Larue To Its Board Of Directors



8/4/2014 9:01:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Aug. 4, 2014 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, announced today that it has appointed William LaRue to its Board of Directors effective immediately. Mr. LaRue will assume the position of chair of the audit committee.

"We are extremely pleased to have Bill join our Board," said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. "Bill's experience and guidance will be extremely helpful as we continue to advance our development programs and grow our business."

"TRACON has established a strong leadership team, and I look forward to helping the team achieve its strategic mission," commented Mr. LaRue.

Mr. LaRue served as Senior Vice President, Chief Financial Officer and Treasurer of Cadence Pharmaceuticals from June 2006 until its acquisition by Mallinckrodt in March 2014. During this period, he supported Cadence's transition from a development stage to a commercial stage company. Previously, Mr. LaRue served as Senior Vice President and Chief Financial Officer of Micromet, Inc., formerly CancerVax Corporation, a biotechnology company focused on the treatment and control of cancer and as Executive Vice President and Chief Financial Officer of eHelp Corporation, a provider of user assistance software. Mr. LaRue also serves on the board of directors of Neurelis, Inc., a privately-held company. Mr. LaRue received a B.S. in business administration and an M.B.A. from the University of Southern California.

About TRACON

TRACON Pharmaceuticals develops targeted therapies for people with cancer and age-related macular degeneration. The current pipeline includes two clinical-stage product candidates, each addressing a unique cellular process, that are expected to complement currently available therapies. TRACON aims to develop effective and well-tolerated treatments for underserved populations with the ultimate goal of enhancing survival and quality of life. To learn more about the company and its products, visit TRACON's website at www.traconpharma.com.

CONTACT: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 clogan@traconpharma.com

Tracon Pharmaceuticals, Inc. Logo

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES